Nanovibronix (NASDAQ:FEED) Stock Rating Lowered by Wall Street Zen
by Scott Moore · The Cerbat GemNanovibronix (NASDAQ:FEED – Get Free Report) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Sunday.
Separately, Weiss Ratings began coverage on Nanovibronix in a report on Tuesday, January 27th. They issued a “sell (e+)” rating on the stock. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.
Check Out Our Latest Stock Analysis on FEED
Nanovibronix Stock Performance
FEED opened at $1.66 on Friday. The stock has a market capitalization of $1.81 million, a P/E ratio of -0.04 and a beta of 2.09. The business has a 50-day moving average of $2.19. Nanovibronix has a 12 month low of $0.99 and a 12 month high of $88.20.
Insider Activity
In other Nanovibronix news, major shareholder Christian Michael Glibert bought 240,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 14th. The shares were bought at an average cost of $2.67 per share, with a total value of $640,800.00. Following the completion of the purchase, the insider directly owned 240,000 shares of the company’s stock, valued at $640,800. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 5.20% of the stock is owned by insiders.
Nanovibronix Company Profile
Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.
The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.